Medical Cannabis and Cannabinoids
October 13, 2026
Taylor M. McGillis, Hannah P Stevenson, Willow Leland et al.
Cannabidiol (CBD) is a non-intoxicating phytocannabinoid with purported benefits across a range of pediatric conditions. However, the relative nascency of its integration in human populations has precluded a longitudinal safety assessment when used during different developmental periods. We hypothesized that CBD’s pharmacodynamic actions underlying the purported therapeutic effects could impact...
Medical Cannabis and Cannabinoids
June 25, 2025
Lakshmi Kumar, Tory R Spindle, C. Austin Zamarripa et al.
Introduction: Cannabis contains hundreds of chemical constituents beyond delta-9-tetrahydrocannabinol (Δ9-THC), which is thought to be the primary driver of most of its acute pharmacodynamic effects. The entourage effect theory asserts that the pharmacological and therapeutic effects of cannabis are not solely attributable to Δ9-THC but are influenced by other constituents, such as minor...
Medical Cannabis and Cannabinoids
February 23, 2024
Alexander Beletsky, Cherry Liu, Bryson Lochte et al.
Abstract Introduction: Cannabis has been reported to have both anxiogenic and anxiolytic effects. Habitual cannabis use has been associated with anxiety disorders (AD). The causal pathways and mechanisms underlying the association between cannabis use (CU)/cannabis use disorder (CUD) and anxiety remain unclear. We examined the literature via a systematic review to investigate the link between...
Medical Cannabis and Cannabinoids
February 13, 2024
Charles N. Zawatsky, Sara Mills-Huffnagle, Corinne M. Augusto et al.
Background: In this review, we summarize current scientific knowledge on psychoactive cannabinoids synthesized from cannabidiol (CBD) and sold in the semi-legal market established in response to the passage of the US Agriculture Improvement Act of 2018, commonly known as the 2018 Farm Bill. The discussion focuses on recent developments that suggest this unregulated market may be fertile ground...
Medical Cannabis and Cannabinoids
October 3, 2023
Mpp Amie Goodin, John Crump, D. Fadool et al.
Background: Ketamine is an anesthetic that has been proven to treat chronic pain via clinical trials; yet there is a gap in knowledge regarding the impact of the concomitant use of ketamine and cannabis on pain severity. This study examined cannabis consumers who participated in a pilot Ketamine-Assisted Psychotherapy (KAP) intervention study to examine pain severity. Methods: A subanalysis of...
Medical Cannabis and Cannabinoids
June 12, 2018
Jürg Gertsch
The botanical drug cannabis flos (inflorescence of Cannabis sativa L.) has a unique popular status as being a potent recreational drug and bona fide universal remedy (panacea). Generally, cannabinoids exert therapeutic effects in a broad range of pathophysiologies related to inflammation, pain, metabolic and stress-related conditions in preclinical animal models. However, the translation of...
Medical Cannabis and Cannabinoids
June 12, 2018
Pascale Meyer, Manuela Langos, Rudolf Brenneisen
Background: Due to variable absorption and extensive first-pass metabolism, the bioavailability of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is low, and, therefore, alternative application forms are necessary. Methods: In an open-label, 2-period phase-1 study on 11 healthy volunteers, a combination of THC and CBD was compared by pulmonary (inh) and intravenous (iv)...